Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs
Abstract
1. Mood State Fluctuations
1.1. Drug Withdrawal and Repetitive Mood Vacillation
1.2. Related Psychobiological Problems
2. Homeostasis
Psychiatric Aspects
3. Neurocognitive Deficits
4. Final Overview
Conflicts of Interest
References
- Cruickshank, C.C.; Dyer, K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104, 1085–1099. [Google Scholar] [CrossRef] [PubMed]
- Hall, W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015, 110, 19–35. [Google Scholar] [CrossRef] [PubMed]
- Panenka, W.K.; Procyshyn, R.M.; Lecomte, T.; MacEwan, G.W.; Flynn, S.W.; Honer, W.G.; Barr, A.M. Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013, 129, 167–179. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Why all stimulant drugs are damaging to recreational users: An empirical overview and psychobiological explanation. Hum. Psychopharmacol. 2015, 30, 213–224. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.; Morinan, A.; Moss, M.; Scholey, A. Understanding Drugs and Behaviour; John Wiley & Sons: Chichester, UK, 2004. [Google Scholar]
- Schifano, F.; Albanese, A.; Fergus, S.; Stair, J.L.; Deluca, P.; Corraza, O. Mephedrone (4-methylmethcathinone; ‘meow meow’): Chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214, 593–602. [Google Scholar] [CrossRef] [PubMed]
- Freeman, T.P.; Morgan, C.J.A.; Vaughn-Jones, J.; Hussain, N.; Karimi, K.; Curran, V.H. Cognitive and subjective effects of mephedrone and factors influencing use of a new ‘legal high’. Addiction 2011, 107, 792–800. [Google Scholar] [CrossRef] [PubMed]
- Gurney, S.M.; Scott, K.S.; Kacinko, S.L.; Presley, B.C.; Logan, B.K. Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. Forensic. Sci. Rev. 2014, 26, 53–78. [Google Scholar] [PubMed]
- Jones, L.; Reed, P.; Parrott, A.C. Mephedrone and MDMA: A comparison of their acute and chronic effects, as described by young recreational polydrug users. J. Psychopharmacol. 2016, in press. [Google Scholar]
- Parrott, A.C. Individual differences in stress and arousal during cigarette smoking. Psychopharmacology 1994, 115, 389–396. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Does cigarette smoking cause stress? Am. Psychol. 1999, 54, 817–820. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Nicotine psychobiology: How chronic-dose prospective studies can illuminate some of the theoretical issues from acute-dose research. Psychopharmacology 2006, 184, 567–576. [Google Scholar] [CrossRef] [PubMed]
- Volkow, N.D.; Baler, R.D.; Compton, W.M.; Weiss, S.R.B. Adverse Health Effects of Marijuana Use. N. Engl. J. Med. 2014, 370, 2219–2227. [Google Scholar] [CrossRef] [PubMed]
- Kirkpatrick, M.G.; Gunderson, E.W.; Perez, A.Y.; Haney, M.; Foltin, R.W.; Hart, C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2012, 219, 109–122. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Gibbs, A.; Scholey, A.B.; King, R.; Owens, K.; Swann, P.; Ogden, E.; Stough, C. MDMA and methamphetamine: Some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 2011, 215, 527–536. [Google Scholar] [CrossRef] [PubMed]
- Murgraff, V.; Parrott, A.C.; Bennett, P. Risky single occasion drinking amongst young people: Definition, correlates, policy and intervention. A broad overview of research findings. Alcohol Alcohol. 1998, 33, 3–14. [Google Scholar] [CrossRef][Green Version]
- Parrott, A.C.; Drayson, R.; Henry, L.A. Alcohol: Drink less and live more. J. Alcohol Drug Depend. Subst. Abuse 2016, 2, 4. [Google Scholar]
- Le Strat, Y.; Ramoz, N.; Horwood, J.; Falissard, B.; Hassler, C.; Romo, L.; Gorwood, P. First positive reactions to cannabis constitute a priority risk factor for cannabis dependence. Addiction 2009, 104, 1710–1717. [Google Scholar] [CrossRef] [PubMed]
- Liechti, M.E.; Gamma, A.; Vollenweider, F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001, 154, 161–168. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology 2007, 191, 181–193. [Google Scholar] [CrossRef] [PubMed]
- Bouso, J.C. Using MDMA in the treatment of post-traumatic stress disorder. In Ecstasy: The Complete Guide; Holland, J., Ed.; Park Street Press: Rochester, NY, USA, 2001. [Google Scholar]
- Greer, G.; Tolbert, R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoact. Drugs 1986, 18, 319–327. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. MDMA assisted psychotherapy—A psychobiological perspective and critique. In International Handbook of Psychobiology; Murphy, P., Ed.; Routledge: Abingdon-on-Thames, UK, 2018. [Google Scholar]
- Parrott, A.C. The potential dangers of using MDMA for psychotherapy. J. Psychoactive Drugs 2014, 46, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Reid, L.W.; Elifson, K.W.; Sterk, C.E. Hug drug or thug drug? Ecstasy use and aggressive behavior. Violence Vict. 2007, 22, 104–119. [Google Scholar] [CrossRef] [PubMed]
- Rugani, F.; Bacciardi, S.; Rovai, L.; Pacini, M.; Maremmani, A.G.I.; Deltito, J.; Dell’Osso, L.; Maremmani, I. Symptomatological features of patients with and without ecstasy use during their first psychotic episode. Int. J. Environ. Res. Pub. Health 2012, 9, 2283–2292. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research. Hum. Psychopharmacol. 2013, 28, 289–307. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Evans, L.J.; Howells, J.; Robart, R. Cocaine versus Ecstasy/MDMA: Comparative effects on mood and cognition in recreational users. Open Addict. J. 2011, 4, 36–37. [Google Scholar] [CrossRef][Green Version]
- Seely, K.A.; Lapoint, J.; Moran, J.H.; Fattore, L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 39, 234–243. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Drug taking–for better or for worse? Psychologist 2008, 21, 924–927. [Google Scholar]
- Mello, N.K. Hormones, nicotine, and cocaine: Clinical studies. Hormones Behav. 2010, 58, 57–71. [Google Scholar] [CrossRef] [PubMed]
- Mangan, G.L.; Golding, J.F. The Psychopharmacology of Smoking; Oxford University Press: Oxford, UK, 1986. [Google Scholar]
- Parrott, A.C.; Winder, G. Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: Comparative effects upon vigilance and heart rate. Psychopharmacology 1989, 97, 257–261. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Nesbitt’s Paradox resolved? Stress and arousal modulation during cigarette smoking. Addiction 1998, 93, 27–39. [Google Scholar] [CrossRef] [PubMed]
- Cadet, J.L.; Krasnova, I.; Jayanthi, S.; Lyles, J. Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms. Neurotox. Res. 2007, 11, 183–202. [Google Scholar] [CrossRef] [PubMed]
- Carvalho, M.; Carmo, H.; Costa, V.M.; Capela, J.P.; Pontes, H.; Remiao, F. Toxicology of amphetamines: An update. Arch. Toxicol. 2013, 86, 1167–1231. [Google Scholar] [CrossRef] [PubMed]
- Aden, A.; Dimba, E.A.; Neola, U.M.; Chindia, M.L. Socio-economic effects of khat chewing in north eastern Kenya. East Afr. Med. J. 2006, 83, 69–73. [Google Scholar] [PubMed]
- Parrott, A.C. Drug related harm: A complex and difficult concept to scale. Hum. Psychopharmacol. 2007, 22, 423–425. [Google Scholar] [CrossRef] [PubMed]
- Curran, H.V.; Travill, R.A. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): Weekend “high” followed by mid-week “low”. Addiction 1997, 92, 821–831. [Google Scholar] [PubMed]
- Curran, H.V.; Rees, H.; Hoare, T.; Hoshi, R.; Bond, A. Empathy and aggression: Two faces of ecstasy? A study of interpretive cognitive bias and mood change in ecstasy users. Psychopharmacology 2004, 173, 425–433. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Lasky, J. Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 1998, 139, 261–268. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Lock, J.; Conner, A.C.; Kissling, C.; Thome, J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008, 57, 165–180. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol. 2005, 19, 71–83. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘Ecstasy’ users. Neurosci. Biobehav. Rev. 2013, 37, 1466–1484. [Google Scholar] [CrossRef] [PubMed]
- Vandrey, R.G.; Budney, A.J.; Moore, B.A.; Hughes, J.R. A cross-study comparison of cannabis and tobacco withdrawal. Am. J. Addict. 2005, 14, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Budney, A.J.; Hughes, J.R.; Moore, B.A.; Novy, P.L. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch. Gen. Psychiatry 2001, 58, 917–924. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Budney, A.J.; Novy, P.L.; Hughes, J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94, 1311–1322. [Google Scholar] [CrossRef] [PubMed]
- Heishman, S.J.; Singleton, E.G.; Liguori, A. Marijuana Craving Questionnaire: Development and initial validation of a self-report instrument. Addiction 2001, 96, 1023–1034. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Hayley, A.; Downey, L. Recreational stimulants, herbal and spice cannabis: The core psychobiological processes that underlie their damaging effects. Hum. Psychopharmacol. 2017, 32, E2594. [Google Scholar] [CrossRef] [PubMed]
- Heffernan, T.M.; Ling, J.; Parrott, A.C.; Buchanan, T.; Scholey, A.B.; Rodgers, J. Self-rated everyday and prospective memory abilities of cigarette smokers and non-smokers: A web based study. Drug Alcohol Depend. 2005, 78, 235–241. [Google Scholar] [CrossRef] [PubMed]
- Glasner-Edwards, S.; Mooney, L.J. Methamphetamine psychosis: Epidemiology and management. CNS Drugs 2014, 28, 1115–1126. [Google Scholar] [CrossRef] [PubMed]
- Soar, K.; Mason, C.; Potton, A.; Dawkins, L. Neuropsychological effects associated with recreational cocaine use. Psychopharmacology 2012, 222, 633–643. [Google Scholar] [CrossRef] [PubMed]
- Copeland, J.; Clement, N.; Swift, W. Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry 2014, 4, 55–63. [Google Scholar] [CrossRef]
- De Luca, M.A.; Castelli, M.P.; Loi, B.; Porcu, A.; Martorelli, M.; Miliano, C.; Kellett, K.; Davidson, C.; Stair, J.L.; Schifano, F.; et al. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology 2015, 105, 630–638. [Google Scholar] [CrossRef] [PubMed]
- Downey, L.A.; Verster, J.C. Cannabis Concerns: Increased potency, availability and synthetic analogues. Curr. Drug Abuse Rev. 2014, 7, 67–68. [Google Scholar] [CrossRef] [PubMed]
- Papanti, D.; Schifano, F.; Botteon, G.; Bertossi, F.; Mannix, J.; Vidoni, D.; Bonavigo, T. “Spiceophrenia”: A systematic overview of “Spice”-related psychopathological issues and a case report. Hum. Psychopharmacol. 2013, 28, 379–389. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Orsolini, L.; Papanti, G.D.; Corkery, J. Novel psychoactive substances of interest for psychiatry. World Psychiatry 2015, 14, 15–26. [Google Scholar] [CrossRef] [PubMed]
- Zimmermann, U.S.; Winklemann, P.R.; Pilhatsch, M.; Nees, J.A.; Spanagel, R.; Schulz, K. Withdrawal phenomena and dependence syndrome after the cousumption of “spice gold”. Dtsch. Arztebl. Int. 2009, 106, 464–467. [Google Scholar] [PubMed]
- Herrmann, E.S.; Weerts, E.M.; Vandrey, R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp. Clin. Psychopharmacol. 2015, 23, 415–421. [Google Scholar] [CrossRef] [PubMed]
- Wagner, F.A.; Anthony, J.C. From First Drug Use to Drug Dependence–Developmental Periods of Risk for Dependence upon Marijuana, Cocaine, and Alcohol. Neuropsychopharmacology 2002, 26, 479–488. [Google Scholar] [CrossRef]
- Terry, P.; Wright, K.A.; Cochrane, R. Factors contributing to changes in frequency of cannabis consumption by cannabis users in England: A structured interview study. Addict. Res. Theory 2007, 15, 113–119. [Google Scholar] [CrossRef]
- Silins, E.; Horwood, L.J.; Patton, G.C.; Fergusson, D.M.; Olsson, C.A.; Hutchinson, D.M.; Mattick, R.P. Young adult sequelae of adolescent cannabis use: An integrative analysis. Lancet Psychiatry 2014, 1, 286–293. [Google Scholar] [CrossRef]
- Selye, H. The Stress of Life; McGraw Hill: New York, NY, USA, 1956. [Google Scholar]
- Lovallo, W.R. Stress and Health: Biological and Psychological Interactions; Sage: Kern County, CA, USA, 1997. [Google Scholar]
- Parrott, A.C. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): Neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology 2009, 60, 148–158. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. Oxytocin, cortisol and MDMA (3,4-methylenedioxymethamphetamine): Neurohormonal aspects of recreational ‘Ecstasy’. Behav. Pharmacol. 2016, 27, 649–658. [Google Scholar] [CrossRef] [PubMed]
- Harris, D.S.; Baggott, M.; Mendelson, J.H.; Mendelson, J.E.; Jones, R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162, 396–405. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Adnum, L.; Evans, A.; Kissling, C.; Thome, J. Heavy Ecstasy/MDMA use at cool house parties: Substantial cortisol release and increased body temperature. J. Psychopharmacol. 2007, 21, 35. [Google Scholar]
- Wetherell, M.A.; Montgomery, C. Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users. Psychopharmacology 2013, 231, 1365–1375. [Google Scholar] [CrossRef] [PubMed]
- Ogeil, R.P.; Rajaratnam, S.M.; Broadbear, J.H. Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes. Drug Alcohol Depend. 2013, 132, 223–230. [Google Scholar] [CrossRef] [PubMed]
- Freedman, R.R.; Johanson, C.E.; Tancer, M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2005, 183, 248–256. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans. Drug Alcohol Depend. 2012, 121, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Young, L. Saturday night fever in ecstasy/MDMA dance clubbers: Heightened body temperature and associated psychobiological changes. Temperature 2015, 3, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Canazza, I.; Ossato, A.; Trapella, C.; Fantinati, A.; De Luca, M.A.; Margiani, G.; Vincenzi, F.; Rimondo, C.; Di Rosa, F.; Gregori, A. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology 2016, 233, 3685–3709. [Google Scholar] [CrossRef] [PubMed]
- Alsufyani, H.A. Cardiovascular and Temperature Actions of Cathinones. Ph.D. Thesis, Royal College of Surgeons in Ireland, Dublin, Ireland, 2017. [Google Scholar]
- Parrott, A.C.; Sands, H.R.; Jones, L.; Clow, A.; Evans, P.; Downey, L.; Stalder, T. Increased cortisol levels in hair of recent Ecstasy/MDMA users. Eur. Neuropsychopharmacol. 2014, 24, 369–374. [Google Scholar] [CrossRef] [PubMed]
- Ranganathan, M.; Braley, G.; Pittman, B.; Cooper, T.; Perry, E.; Krystal, J.; D’Souza, D.C. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology 2009, 203, 737–744. [Google Scholar] [CrossRef] [PubMed]
- King, G.R.; Ernst, T.; Deng, W.; Stenger, A.; Gonzales, R.M.K.; Nakama, H.; Chang, L. Effects of chronic active cannabis use on visuomotor integration, in relation to brain activation and cortisol levels. J. Neurosci. 2011, 31, 17923–17931. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C. MDMA in humans: Factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bio-energetic stress. J. Psychopharmacol. 2006, 20, 147–163. [Google Scholar] [CrossRef] [PubMed]
- Nung, S. The Divine Farmer’s Materia Medica Classic; Blue Poppy Press: Boulder, CO, USA, 1998. [Google Scholar]
- Ashton, C.H. Pharmacology and effects of cannabis: A brief review. Br. J. Psychiatry 2001, 178, 101–106. [Google Scholar] [CrossRef] [PubMed]
- D’Souza, D.C.; Perry, E.; MacDougall, L.; Ammerman, Y.; Cooper, T.; Yu-Te, W.; Krystal, J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004, 29, 1558–1572. [Google Scholar] [CrossRef] [PubMed]
- Nottage, J.; Stone, J.; Murray, R.; Sumich, A.; Bramon-Bosch, E.; Ffytche, D.; Morrison, P. Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis. Psychopharmacology 2015, 232, 519–528. [Google Scholar] [CrossRef] [PubMed]
- Paparelli, A.; Di Forti, M.; Morrison, P.D.; Murray, R.M. Drug-induced psychosis: How to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front. Behav. Neurosci. 2011, 5. [Google Scholar] [CrossRef] [PubMed]
- Andréasson, S.; Engström, A.; Allebeck, P.; Rydberg, U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet 1987, 330, 1483–1486. [Google Scholar] [CrossRef]
- Le Bec, P.Y.; Fatséas, M.; Denis, C.; Lavie, E.; Auriacombe, M. Cannabis and psychosis: Search of a causal link through a critical and systematic review. L'Encephale 2009, 35, 377–385. (In French) [Google Scholar] [CrossRef] [PubMed]
- Henquet, C.; Krabbendam, L.; Spauwen, J.; Kaplan, C.; Lieb, R.; Wittchen, H.-U.; Van Os, J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br. Med. J. 2005, 330, 11. [Google Scholar] [CrossRef] [PubMed]
- Bovasso, G.B. Cannabis abuse as a risk factor for depressive symptoms. Am. J. Psychiatry 2014, 158, 2033–2037. [Google Scholar] [CrossRef] [PubMed]
- Richardson, T. Cannabis use and mental health: A review of recent epidemiological research. Int. J. Pharmacol. 2010, 6, 796–807. [Google Scholar] [CrossRef]
- Feyissa, A.M.; Kelly, J.P. A review of the neuropharmacological properties of khat. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2008, 32, 1147–1166. [Google Scholar] [CrossRef] [PubMed]
- Vearrier, D.; Greenberg, M.I.; Miller, S.N.; Okaneku, J.T.; Haggerty, D.A. Methamphetamine: History, pathophysiology, adverse mental health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis. Mon. 2012, 58, 38–89. [Google Scholar] [CrossRef] [PubMed]
- Brière, F.N.; Fallu, J.S.; Janosz, M.; Pagani, L.S. Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J. Epidemiol. Community Health 2012, 66, 990–994. [Google Scholar] [CrossRef] [PubMed]
- MacInnes, N.; Handley, S.L.; Harding, G.F. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J. Psychopharmacol. 2001, 15, 181–186. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Montgomery, C.A.; Wetherell, M.A.; Downey, L.A.; Stough, C.; Scholey, A.B. MDMA, cortisol, and heightened stress in recreational Ecstasy/MDMA users. Behav. Pharmacol. 2014, 25, 458–472. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Milani, R.M.; Parmar, R.; Turner, J.J.D. Recreational Ecstasy/MDMA and other drug users form the UK and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology 2001, 159, 77–82. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Di Furia, L.; Forza, G.; Minicuci, N.; Bricolo, R. MDMA (‘ecstasy’) consumption in the context of polydrug abuse: A report on 150 patients. Drug Alcohol Depend. 1998, 52, 85–90. [Google Scholar] [CrossRef]
- Scholey, A.B.; Owen, L.; Gates, J.; Rodgers, J.; Buchanan, T.; Ling, J.; Heffernan, T.; Swan, P.; Stough, C.; Parrott, A.C. Hair MDMA samples are consistent with reported Ecstasy use: Findings from an internet study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 2011, 63, 15–21. [Google Scholar] [CrossRef] [PubMed]
- Taurah, L.; Chandler, C.; Sanders, G. Depression, impulsiveness, sleep and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology 2014, 231, 737–751. [Google Scholar] [CrossRef] [PubMed]
- Turner, J.J.D.; Singer, L.T.; Moore, D.G.; Min, M.O.; Goodwin, J.; Fulton, S.; Parrott, A.C. Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: Reduced depression one year after giving birth and quitting Ecstasy. J. Psychopharmacol. 2014, 28, 55–66. [Google Scholar] [CrossRef] [PubMed]
- Downey, L.A.; Tysse, B.; Ford, T.C.; Samuels, A.C.; Wilson, R.P.; Parrott, A.C. Psychomotor tremor and proprioceptive control problems in current and former stimulant drug users: An accelerometer study of heavy users of amphetamine, MDMA, and other recreational stimulants. J. Clin. Pharmacol. 2017, 57, 1330–1337. [Google Scholar] [CrossRef] [PubMed]
- Vonmoos, M.; Hulka, L.M.; Preller, K.H.; Jenni, D.; Baumgartner, M.R.; Stohler, R.; Bolla, K.I.; Quednow, B.B. Cognitive dysfunction in recreational and dependent cocaine users: Role of attention-deficit hyperactivity disorder, craving and early age at onset. Br. J. Psychiatry 2014, 203, 35–43. [Google Scholar] [CrossRef] [PubMed]
- Fisk, J.E.; Montgomery, C.; Wareing, M.; Murphy, P.N. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology 2005, 181, 550–559. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Fox, H.; Parrott, A.C.; Turner, J.J.D. Ecstasy/MDMA related cognitive deficits: A function of dosage rather than awareness of problems. J. Psychopharmacol. 2001, 15, 273–281. [Google Scholar] [CrossRef] [PubMed]
- Fox, H.C.; McLean, A.; Turner, J.J.D.; Parrott, A.C.; Rogers, R.; Sahakian, B.J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (“ecstasy”) polydrug users. Psychopharmacology 2002, 162, 203–214. [Google Scholar] [CrossRef] [PubMed]
- Laws, K.R.; Kokkalis, J. Ecstasy (MDMA) and memory function: A meta-analytic update. Hum. Psychopharmacol. 2007, 22, 381–388. [Google Scholar] [CrossRef] [PubMed]
- Montgomery, C.; Hatton, N.P.; Fisk, J.E.; Ogden, R.S.; Jansari, A. Assessing the functional significance of ecstasy-related memory deficits using a virtual reality paradigm. Hum. Psychopharmacol. 2010, 25, 318–325. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Lees, A.; Garnham, N.J.; Jones, M.; Wesnes, K. Cognitive performance in recreational users of MDMA or “ecstasy”: Evidence for memory deficits. J. Psychopharmacol. 1998, 12, 79–83. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Downey, L.A.; Roberts, C.A.; Montgomery, C.; Bruno, R.; Fox, H.C. Recreational 3.4-methylenedioxymethamphetamine or ‘ecstasy’: Current perspective and future research needs. J. Psychopharmacol. 2017, 31, 959–966. [Google Scholar] [CrossRef] [PubMed]
- Bolla, K.I.; Brown, K.; Eldreth, D.; Tate, K.; Cadet, J.L. Dose-related neurocognitive effects of marijuana use. Neurology 2002, 59, 1337–1343. [Google Scholar] [CrossRef] [PubMed]
- Grant, I.; Gonzalez, R.; Carey, C.L.; Natarajan, L.; Wolfson, T. Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. J. Int. Neuropsychol. Soc. 2003, 9, 679–689. [Google Scholar] [CrossRef] [PubMed]
- Jager, G.; Block, R.I.; Luijten, M.; Ramsey, N.F. Cannabis use and memory brain function in adolescent boys: A cross-sectional multicenter fMRI study. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49, 561–572. [Google Scholar] [CrossRef] [PubMed]
- Meier, M.H.; Caspi, A.; Ambler, A.; Harrington, H.; Houts, R.; Keefe, R.S.E.; Moffitt, T.E. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Nat. Acad. Sci. USA 2012, 109, E2657–E2664. [Google Scholar] [CrossRef] [PubMed]
- Pope, H.G.; Gruber, A.J.; Hudson, J.I.; Huestis, M.A.; Yurgelun-Todd, D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 2001, 58, 909–915. [Google Scholar] [CrossRef] [PubMed]
- Yücel, M.; Solowij, N.; Respondek, C.; Whittle, S.; Fornito, A.; Pantelis, C.; Lubman, D.I. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008, 65, 694–701. [Google Scholar] [CrossRef] [PubMed]
- Mandelbaum, D.E.; de la Monte, S.M. Adverse structural and functional effects of marijuana on the brain: Evidence reviewed. Pediatric Neurol. 2017, 66, 12–20. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Parrott, A.C. Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs. Brain Sci. 2018, 8, 43. https://doi.org/10.3390/brainsci8030043
Parrott AC. Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs. Brain Sciences. 2018; 8(3):43. https://doi.org/10.3390/brainsci8030043
Chicago/Turabian StyleParrott, Andrew C. 2018. "Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs" Brain Sciences 8, no. 3: 43. https://doi.org/10.3390/brainsci8030043
APA StyleParrott, A. C. (2018). Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs. Brain Sciences, 8(3), 43. https://doi.org/10.3390/brainsci8030043